Prevention of SARS-Cov 2 infection. EHPAD (nursing home) will be selected for the study in case of the diagnosis of at least one resident with a documented SRAS-Cov 2 infection or a suspected COVID-19 (Fever ≥ 38°C and/or cough, thoracic pain or dyspnea) within the last 14 days. 1.Resident living is an open nurse home 2.Resident without symptom of COVID-19 3.No imatinib contra-indication 4.Signed informed consent Prevention of severe COVID-19 1.Patient aged > 70y 2.Patient with a documented SRAS-Cov 2 infection (if no test is available, suspected SARS-Cov 2 infection). 3.Initial phase (7 days) of COVID-19 4.Signed informed consent

Prevention of SARS-Cov 2 infection. EHPAD (nursing home) will be selected for the study in case of the diagnosis of at least one resident with a documented SRAS-Cov 2 infection or a suspected COVID-19 (Fever ≥ 38°C and/or cough, thoracic pain or dyspnea) within the last 14 days. 1.Resident living is an open nurse home 2.Resident without symptom of COVID-19 3.No imatinib contra-indication 4.Signed informed consent Prevention of severe COVID-19 1.Patient aged > 70y 2.Patient with a documented SRAS-Cov 2 infection (if no test is available, suspected SARS-Cov 2 infection). 3.Initial phase (7 days) of COVID-19 4.Signed informed consent